

# **Rapid and scalable characterization of CRISPR technologies using an *E. coli* cell-free transcription-translation system**

Ryan Marshall<sup>1\*</sup>, Colin S. Maxwell<sup>2\*</sup>, Scott P. Collins<sup>2</sup>, Michelle L. Luo<sup>2</sup>, Thomas Jacobsen<sup>2</sup>,  
Chase L. Beisel<sup>2†</sup>, Vincent Noireaux<sup>1†</sup>

<sup>1</sup>School of Physics and Astronomy

University of Minnesota, Minneapolis, MN, 55455

<sup>2</sup>Department of Chemical and Biomolecular Engineering

North Carolina State University, Raleigh, NC 27695

\*These authors contributed equally to this work

†Correspondence directed to [cbeisel@ncsu.edu](mailto:cbeisel@ncsu.edu) (C.L.B.) and [noireaux@umn.edu](mailto:noireaux@umn.edu) (V.N.)

Key words: Cas9, Cascade, Cpf1, PAM, prototyping, synthetic biology, TXTL

Running title: Characterizing CRISPR with TXTL

1 **ABSTRACT**

2 CRISPR-Cas systems have offered versatile technologies for genome engineering, yet their  
3 implementation has been outpaced by the ongoing discovery of new Cas nucleases and anti-  
4 CRISPR proteins. Here, we present the use of *E. coli* cell-free transcription-translation systems  
5 (TXTL) to vastly improve the speed and scalability of CRISPR characterization and validation.  
6 Unlike prior approaches that require protein purification or live cells, TXTL can express active  
7 CRISPR machinery from added plasmids and linear DNA, and TXTL can output quantitative  
8 dynamics of DNA cleavage and gene repression. To demonstrate the applicability of TXTL, we  
9 rapidly measure guide RNA-dependent DNA cleavage and gene repression for single- and  
10 multi-effector CRISPR-Cas systems, accurately predict the strength of gene repression in *E.*  
11 *coli*, quantify the inhibitory activity of anti-CRISPR proteins, and develop a fast and scalable  
12 high-throughput screen for protospacer-adjacent motifs. These examples underscore the  
13 potential of TXTL to facilitate the characterization and application of CRISPR technologies  
14 across their many uses.

## 15 INTRODUCTION

16 CRISPR technologies have proven to be broadly useful genome-editing tools for biomolecular  
17 research, biotechnology, human health, and agriculture (Barrangou and Doudna, 2016). These  
18 technologies rely on RNA-guided nucleases derived from prokaryotic CRISPR-Cas immune  
19 systems (Mohanraju et al., 2016). The nuclease specifically cleaves DNA or RNA sequences  
20 complementary to the guide portion of the RNA and flanked by a protospacer-adjacent motif  
21 (PAM), allowing programmable DNA damage or repair-mediated genome editing. Furthermore,  
22 by disrupting endonuclease activity, these nucleases can be readily converted into  
23 programmable nucleic-acid binding proteins, and used for applications in gene regulation, base  
24 editing, and real-time imaging (Chen et al., 2016; Dominguez et al., 2016; Komor et al., 2017;  
25 Nelles et al., 2016).

26 While the vast majority of CRISPR-based technologies have relied on the DNA-targeting  
27 Cas9 nuclease from *Streptococcus pyogenes* (Barrangou and Doudna, 2016; Jinek et al.,  
28 2012), nature boasts a diverse collection of CRISPR-Cas systems that are currently sub-divided  
29 into two classes, six types, and 33 subtypes (Koonin et al., 2017; Makarova et al., 2015;  
30 Shmakov et al., 2015). Interrogation of the emerging subtypes have revealed nucleases with  
31 widely varying properties that can be smaller, recognize different PAMs, degrade DNA, target  
32 RNA, exhibit reduced propensity for off-target effects, or are more amenable to multiplexing in  
33 comparison to SpyCas9 (Abudayyeh et al., 2016; Kim et al., 2017; Kleinstiver et al., 2016;  
34 Mulepati and Bailey, 2013; Zetsche et al., 2017). Separately, the discovery of anti-CRISPR  
35 proteins that inhibit Type I-E, I-F, II-A, and II-C CRISPR-Cas systems offer means to tightly  
36 control nuclease activity (Bondy-Denomy et al., 2015; Pawluk et al., 2016a; Pawluk et al.,  
37 2016b; Rauch et al., 2017), with the likely existence of similar inhibitors for the other subtypes.  
38 However, despite this diversity, the vast majority of these proteins have been slow to be  
39 adopted as CRISPR technologies.

40 One major bottleneck is the characterization of these proteins' basic properties and  
41 functions. To date, characterization has been performed with multiple methodologies based on  
42 *in vitro* biochemical assays or live cells. More recently, these assays have been modified for  
43 high-throughput analysis of PAM binding requirements, off-target propensities, or large libraries  
44 of guide RNAs through next-generation sequencing or imaging of arrayed nucleotides  
45 (Abudayyeh et al., 2016; Boyle et al., 2017; Jiang et al., 2013; Karvelis et al., 2015; Kleinstiver  
46 et al., 2016; Leenay et al., 2016; Pattanayak et al., 2013; Tsai et al., 2017). However, these  
47 assays consistently require days to weeks to perform due to the requirement for protein  
48 purification or for culturing and transforming live cells. Furthermore, these assays scale poorly  
49 when testing large sets of proteins or guide RNAs. Given the growing abundance of known  
50 CRISPR nucleases, the ease in guide rna design, and the growing prevalence of factors factors  
51 that interface with CRISPR-Cas systems, there remains a pressing need to develop rapid and  
52 scalable characterization methodologies.

53 Here, we address this need using an *Escherichia coli* cell-free transcription-translation  
54 system (TXTL) (Garamella et al., 2016; Shin and Noireaux, 2012). TXTL recapitulates gene  
55 expression and enzymatic activity following the addition of template DNA, allowing the  
56 quantitative and dynamic measurement of nuclease binding and cleavage at microliter scale in a  
57 few hours -- all without protein purification or live cells. We demonstrate the utility of TXTL  
58 across a diverse set of Cas nucleases and show how it can be used to predict guide RNA  
59 activity *in vivo*, characterize anti-CRISPR proteins, and elucidate recognized PAMs. Based on  
60 these findings, we expect TXTL to provide a powerful characterization tool for the expanding  
61 universe of CRISPR-Cas systems and proteins, and we show the applicability of TXTL beyond  
62 biomanufacturing, diagnostics, and genetic circuit prototyping (Carlson et al., 2011; Dudley et  
63 al., 2014; Garamella et al., 2016; Gootenberg et al., 2017; Hockenberry and Jewett, 2012;  
64 Jewett et al., 2008; Kanter et al., 2007; Karzbrun et al., 2014; Pardee et al., 2016; Sun et al.,  
65 2014; Swartz, 2006; Takahashi et al., 2015a; Takahashi et al., 2015b; Tayar A., 2015).

66

## 67 **RESULTS**

68 **SpyCas9 and dSpyCas9 exhibit robust activity in TXTL.** We initially examined the activity of  
69 the SpyCas9 nuclease. To monitor the dynamics of DNA cleavage by SpyCas9, we designed  
70 single-guide RNAs (sgRNAs) that target within the promoter, 5' untranslated region (UTR), and  
71 coding sequence of a deGFP reporter construct, a slightly modified version of eGFP with  
72 identical fluorescent properties (Shin and Noireaux, 2012). We then measured the dynamics of  
73 deGFP production following the addition of the SpyCas9 plasmid, linear DNA encoding the  
74 sgRNA, and the deGFP reporter plasmid (Figure 1A). The resulting fluorescence values were  
75 converted to a true reporter concentration based on a calibration curve made with purified  
76 eGFP. We found that the three tested sgRNAs resulted in greatly reduced deGFP  
77 concentrations in comparison to a non-targeting sgRNA after 16 hours in the TXTL reaction  
78 (Figure 1B). Measurable repression was observed beginning after less than one hour into the  
79 TXTL reaction, indicating that this time span was required to express and assemble the Cas9-  
80 sgRNA ribonucleoprotein complex (RNP) and for the complex to bind and cleave the target DNA  
81 (Figure S1A,B). The rate of deGFP production then dropped quickly to approximately zero,  
82 consistent with irreversible DNA cleavage as confirmed by PCR amplification of the target site  
83 (Figure S1C). Interestingly, the onset and of deGFP repression and the rate at which deGFP  
84 production dropped varied depending on the sgRNA used (Figure S1A,B), suggesting that  
85 varying efficiency by which different guides targeted Cas9 to DNA. These results indicate that  
86 an active SpyCas9-sgRNA complex can be expressed directly in TXTL, providing a dynamic  
87 and quantitative readout of nuclease activity in a few hours.

88 We also interrogated the activity of the catalytically-dead version of SpyCas9  
89 (dSpyCas9) commonly used for programmable DNA binding and gene regulation -- also called  
90 CRISPRi and CRISPRa (Gilbert et al., 2014; Qi et al., 2013). DNA binding by dSpyCas9 can  
91 block transcriptional initiation or elongation of RNA polymerase in bacteria, offering a means to

92 link DNA binding with reporter expression in TXTL (Bikard et al., 2013; Qi et al., 2013). To  
93 assess the expression and regulatory activity of dSpyCas9, we measured the concentration of  
94 deGFP over time in TXTL reactions for the same three targeting sgRNAs and the non-targeting  
95 sgRNA. Similar to reactions expressing SpyCas9, reactions expressing dSpyCas9 exhibited  
96 consistent deGFP repression, and the rate of deGFP production dropped after less an hour  
97 (Figure S1A,B). The catalytically-dead version repressed expression less strongly and exhibited  
98 some deGFP production even at the end of the TXTL reaction (Figures 1B, S1A). We confirmed  
99 that the dSpyCas9 did not cleave DNA by PCR amplification across the target location (Figure  
100 S1B). We also observed different extents of deGFP fold-repression across the three targeting  
101 sgRNAs similar to repression strengths reported in bacteria (Bikard et al., 2013; Qi et al., 2013).  
102 These results illustrate that dSpyCas9 functions efficiently to repress gene expression in TXTL.  
103 Given the larger span of time in which regulatory activity can be observed for dSpyCas9 than for  
104 SpyCas9 (Figure S1A), we relied on CRISPR-based gene repression for all subsequent  
105 analyses.

106 To assess the scalability of TXTL reactions, we expanded from one promoter to four  
107 promoters each targeted by two sgRNAs and driving expression of deGFP. Each promoter is  
108 dependent on a unique alternative sigma factor ( $\sigma^{28}$ ,  $\sigma^{38}$ ,  $\sigma^{54}$ ) or the T7 RNA polymerase, where  
109 each transcription factor is supplied on an added expression plasmid under the control of a  $\sigma^{70}$   
110 promoter (Garamella et al., 2016; Shin and Noireaux, 2012) (Figure 1C). By including a deGFP-  
111 targeting sgRNA, a non-targeting sgRNA, and a  $\sigma^{70}$  promoter, we tested a total of 50 promoter-  
112 sgRNA combinations, with each combination tested in triplicate. The TXTL reactions confirmed  
113 that measurable repression was only observed when an sgRNA was matched with its target  
114 (Figure 1C), with the strength of repression ranging between 7-fold and 105-fold. We also  
115 targeted binding sites for the NtrC operator sites within the  $\sigma^{54}$  promoter (Figure S2),  
116 demonstrating that these sites were important for reporter expression. In total, we showed that  
117 TXTL can be used to rapidly and scalably assess sgRNA activity.

118

119 **Multiple factors impact the measured activity of dSpyCas9 in TXTL.** After characterizing  
120 SpyCas9 and dSpyCas9 in TXTL, we sought to determine parameters that affect the measured  
121 activity. First, we found that varying the amount of the dSpyCas9 plasmid reduced the total  
122 amount of GFP produced in a TXTL reaction (Figure S2A), suggesting that dSpyCas9 levels  
123 were limiting under these reaction conditions. Surprisingly, adding more dSpyCas9 plasmid  
124 elevated deGFP production for the non-targeting sgRNA, underscoring the need to add the  
125 same total amount of DNA when performing comparative studies such as when comparing the  
126 activity of different targeting sgRNAs.

127 Second, we evaluated the impact of destabilizing deGFP to emulate reporter turnover or  
128 dilution *in vivo*. We appended an *ssrA* degron tag recognized by the ClpXP protease to the C-  
129 terminus of deGFP (Figure 2B) (Schmidt et al., 2009). Appending the *ssrA* tag to deGFP  
130 resulted in an apparent enhancement of dSpyCas9-based repression (Figure 2B) due to the  
131 inability of deGFP to accumulate in the TXTL reaction (Figure S2B). This apparent  
132 enhancement offers a means to measure CRISPR-based repression under conditions that  
133 mimic dilution *in vivo*.

134 We next evaluated the impact of targeting linear versus plasmid DNA. Linear DNA can  
135 be generated without cloning and thus can be readily used in TXTL (Marshall et al., 2017; Sun  
136 et al., 2014). However, some Cas nucleases have been shown to require supercoiled DNA for  
137 binding (Westra et al., 2012), suggesting that relaxed DNA may not efficiently recognize targets  
138 encoded on linear DNA. We measured the extent of dSpyCas9-based repression when  
139 targeting a plasmid or linear version of the deGFP reporter construct. The linear DNA was  
140 generated by PCR including flanks over one kilobase away from the closest target site,  
141 mitigating potential effects from the end of the dsDNA molecule. We measured the fold-  
142 repression of the deGFP produced by the reaction after five hours, which is shorter than our  
143 previous experiments because linear templates degrade after that time in our TXTL system

144 (Marshall et al., 2017). We found that dSpyCas9 was capable of repressing gene expression  
145 when targeting the transcribed sequence of the reporter gene on the linear template, but not  
146 when targeting the promoter (Figure 2C). These results suggest that the dSpyCas9 can block  
147 elongation but not initiation of the *E. coli* RNA polymerase on linear DNA. They also indicate  
148 that Cas nucleases interact differently with linear targets and plasmid targets, underscoring the  
149 need for further interrogation.

150         When DNA expressing dSpyCas9, sgRNA, and reporter plasmid DNA were added  
151 together at the beginning of a TXTL experiment, we observed a transient period in which the  
152 reporter gene was expressed before the onset of dSpyCas9-based repression (Figure 1B). We  
153 hypothesized that this period of transient expression was due to the slow assembly speed of the  
154 dSpyCas9-sgRNA RNP complex. To test this hypothesis, we varied our initial protocol to pre-  
155 express dSpyCas9 and the sgRNA before adding the reporter plasmid for three hours. We  
156 reasoned that this period of pre-expression would allow the RNP to assemble and that this  
157 would shorten the time until we observed repression of the reporter gene. Consistent with our  
158 hypothesis, pre-expressing dSpyCas9 and the sgRNA reduced the time before the reporter  
159 gene was repressed (Figure 2C), with measurable repression occurring as fast as six minutes,  
160 depending on the sgRNA used (Figure S2C,D). We also evaluated the effect of pre-expressing  
161 dSpyCas9 in cells prior to generating the TXTL lysate (Figure S2E). Interestingly, pre-  
162 expression of dSpyCas9 generally did not enhance repression (Figure S2F), suggesting that  
163 expression of the sgRNA and assembly of the ribonucleoprotein complex strongly contribute to  
164 the delayed onset of dSpyCas9-based repression. Taken together, these results suggest that  
165 dCas9 RNP assembly is relatively slow (on the order of 30 minutes), but that DNA binding is  
166 faster (on the order of 5 minutes).

167  
168 **The strength of dSpyCas9-based repression strongly correlates between TXTL and *E.***  
169 ***coli*.** Given the speed and scalability of employing TXTL to characterize CRISPR nucleases and



170 guide RNAs, an ensuing question is how well the quantified activity correlates to *in vivo* settings  
171 and recapitulates known phenomena (Chappell et al., 2013). To begin addressing this question,  
172 we opted to compare dSpyCas9-based repression in TXTL and in *E. coli* by targeting 19  
173 different locations within the deGFP reporter plasmid (Figure 3). The particular locations were  
174 chosen to also evaluate the impact of strong PAMs (NGG) and weak PAMs (NAG) as well as  
175 targeting the template or non-template strand within the promoter or transcribed region. We  
176 chose these comparisons because of poor recognition of NAG PAMs than NGG PAMs by  
177 dCas9 (Boyle et al., 2017; Jiang et al., 2013) and reduced gene repression in bacteria when  
178 targeting the template strand within the transcribed region versus any other location (Bikard et  
179 al., 2013; Qi et al., 2013). The experiments were conducted by encoding the dSpyCas9, sgRNA,  
180 and deGFP reporter on separate, compatible plasmids for parallel testing in TXTL and in *E. coli*,  
181 and fold-repression was calculated based on endpoint measurements of deGFP in comparison  
182 to a non-targeting sgRNA control.

183         These experiments revealed a strong correlation ( $R^2 = 0.90$ ) between the measurements  
184 in TXTL and in *E. coli* (Figure 3). Consistent with this correlation, we observed greatly reduced  
185 repression for targets flanked by NAG PAMs versus NGG PAMs. Furthermore, repression was  
186 consistently weaker when targeting the template strand of the transcribed region in comparison  
187 to targeting the non-template strand of the transcribed region or either strand within the vicinity  
188 of the promoter. This direct comparison therefore showed that TXTL can reasonably predict *in*  
189 *vivo* activity of CRISPR-Cas systems, at least for gene repression by dSpyCas9 in *E. coli*.

190

191 **The activity of other CRISPR nucleases can be measured with TXTL.** Our results showing  
192 that active SpyCas9 RNPs can be expressed in TXTL suggested that other CRISPR-Cas  
193 systems would also function in TXTL. To test this, we evaluated effector proteins from two other  
194 CRISPR-Cas systems: the single-effector nuclease Cpf1 from the Type V-A system in  
195 *Francisella novicida*, and the multi-subunit complex Cascade from the Type I-E system in *E. coli*

196 (Figure 4). These were selected because Cpf1 nucleases exhibits many desirable properties  
197 over Cas9 nucleases while Type I CRISPR-Cas systems are the most prevalent system type in  
198 nature but are more challenging to characterize because multiple proteins form the effector  
199 complex (Makarova et al., 2015; Zetsche et al., 2015). Previous studies have shown that both  
200 systems are both capable of programmable gene repression in bacteria when using a  
201 catalytically-dead version of the nuclease (dFnCpf1) or by expressing Cascade in the absence  
202 of the Cas3 endonuclease, respectively (Leenay et al., 2016; Luo et al., 2015; Rath et al., 2015;  
203 Zetsche et al., 2015). To test CRISPR-based repression for each system, we designed three  
204 guide RNAs (a mature guide RNA for Cpf1, a repeat-spacer-repeat for Cascade) targeting  
205 distinct sites within the P70a promoter, with each site flanked by an appropriate PAM.

206 We first found that dFnCpf1 was capable of repressing gene expression with each of the  
207 three guide RNAs that targeted the reporter gene promoter (Figure 4A). The measured  
208 repression by dFnCpf1 after 16 hours of reaction was weaker than that achieved by dSpyCas9,  
209 which we attribute to the longer delay in the onset of repression (Figure S3A,C). Interestingly,  
210 pre-expressing dFnCpf1 and its guide RNA for three hours reduced the delay in measurable  
211 repression by approximately two hours. This finding suggests that complex assembly and DNA  
212 binding is slower for the FnCpf1-gRNA complex than for the dSpyCas9-sgRNA complex.

213 We also found that EcCascade could elicit gene repression in TXTL despite the need to  
214 coordinately express five proteins. The total reduction of GFP produced by the reaction was  
215 modest because of the delay in the onset of strong repression (Figures 4B and S3B,D).  
216 However, pre-expressing EcCascade and the CRISPR RNA strongly reduced the total amount  
217 of GFP produced due to strong repression shortly after the addition of the reporter plasmid  
218 (Figures 4B and S3B,D), indicating that the complex -- once expressed and assembled -- rapidly  
219 binds DNA and efficiently blocks RNA polymerase recruitment. Unexpectedly, deGFP  
220 production was consistently lower when expressing EcCascade versus any of the other effector  
221 proteins that was exacerbated when EcCascade was pre-expressed (Figure 4B), suggesting

222 that EcCascade is interfering with the expression or activity in deGFP. In total, we show that  
223 TXTL can be extended to the characterization of CRISPR-Cas systems requiring both single-  
224 effector and multi-protein effector complexes.

225

226 **TXTL can quantify the inhibitory activity of anti-CRISPR proteins.** Recently, the discovery  
227 of anti-CRISPR proteins that bind and inhibit Cascade and Cas3 from Type I-E and Type I-F  
228 CRISPR-Cas systems and Cas9 from Type II-A and II-C systems raised the potential of using  
229 these proteins to tightly regulate genome editing and gene regulation (Bondy-Denomy et al.,  
230 2015; Pawluk et al., 2016a; Pawluk et al., 2016b; Rauch et al., 2017). We asked if TXTL could  
231 be used to rapidly assess the inhibitory activity of potential anti-CRISPR proteins. We focused  
232 on AcrIIA2 and AcrIIA4, two anti-CRISPR proteins that were recently reported to inhibit the  
233 activity of SpyCas9 *in vitro* and in human cells (Rauch et al., 2017). To measure the inhibitory  
234 activity of AcrIIA2 and AcrIIA4 against SpyCas9 in TXTL, we encoded each protein on a linear  
235 expression construct that was expressed for two hours in the lysate prepared from cells  
236 expressing dSpyCas9 (Figures 5A, S2E). We then added DNA encoding the GFP reporter  
237 plasmid and linear DNA encoding a targeting or non-targeting sgRNA and measured deGFP  
238 fluorescence over time.

239 We found that both AcrIIA2 and AcrIIA4 counteracted gene repression by dSpyCas9.  
240 However, AcrIIA4 fully restored the amount of deGFP produced by the reaction compared to the  
241 non-targeting control, whereas AcrIIA2 only restored deGFP production by 34%. Therefore,  
242 TXTL can be used to quantify the inhibitory activity of anti-CRISPR proteins, where the resulting  
243 values can guide the rapid identification of potent anti-CRISPR proteins that can more  
244 effectively inhibit Cas nuclease activity.

245

246 **TXTL offers a rapid means of elucidating CRISPR PAMs.** One of the major barriers to the  
247 functional characterization of new Cas nucleases is determining the recognized PAM

248 sequences. While numerous experimental methods have been developed for PAM  
249 determination, they consistently rely on *in vitro* assays that require protein purification or on cell-  
250 based assays that require culturing and transforming of live cells (Karvelis et al., 2017; Leenay  
251 and Beisel, 2017). We therefore asked if TXTL could also be used as the basis of PAM  
252 determination assays to avoid protein purification and exploit the large library sizes that can be  
253 screened with *in vitro* assays. Paralleling prior *in vitro* and *in vivo* DNA cleavage assays (Jiang  
254 et al., 2013; Zetsche et al., 2015), our devised assay relies on introducing a library of potential  
255 PAM sequences flanking a site targeted by an expressed guide RNA and Cas nuclease (Figure  
256 5B). After incubating the pooled PAM library and DNA encoding the Cas nuclease and guide  
257 RNA, the pool of uncleaved target sequences is PCR-amplified and subjected to next-  
258 generation sequencing. By comparing the relative frequency of individual sequences within the  
259 library before and after sequencing, we can quantify the depletion of each library member and  
260 therefore how well the nuclease recognizes each sequence as a PAM. Critically, the assay can  
261 be completed in ~10 hours from when the DNA constructs are in hand to when PCR products  
262 are submitted for sequencing.

263         As a proof-of-principle demonstration, we assessed the PAM requirements of the well-  
264 characterized FnCpf1 nuclease. Previous assays have revealed that FnCpf1 requires a TTN  
265 motif on the 5' end of the target for efficient cleavage using the guide RNA-centric orientation,  
266 although CTN can also be recognized (Fonfara et al., 2016; Leenay et al., 2016; Zetsche et al.,  
267 2015). We created a five-nucleotide library of potential PAM sequences 5' to the guide RNA  
268 target. *In vitro* PAM assays are known to yield less specific PAM sequences for higher nuclease  
269 concentrations (Karvelis et al., 2015), so we assessed the determined PAMs in our assay for  
270 reaction times ranging from one hour to six hours following the addition of the FnCpf1 and guide  
271 RNA expression constructs (Figure S4). Figure 5 depicts the identified PAM sequences based  
272 on the depletion of individual nucleotides at each position (Figure 5C) or specific motifs (Figure  
273 5D) as well as a PAM wheel capturing the relative depletion of each sequence across the library

274 (Figure 5E) (Leenay et al., 2016). We did not include the -5 position in the PAM wheel because  
275 this position showed no appreciable bias across the four possible nucleotides.

276 Our TXTL-based PAM assay recapitulated the canonical 5' TTN PAM for FnCpf1 while  
277 revealing other distinct features. At a reaction time of six hours, NTTTTN was the most active  
278 motif. Within this motif, ATTTA was the most depleted by ~3-fold more than the next most  
279 depleted sequences (Data file S1). We further found that NNCTN also supported efficient  
280 cleavage in line with previous reports (Fonfara et al., 2016; Zetsche et al., 2015), while a T at  
281 the -1 position was detrimental to cleavage. Taken together, these results indicate that a TXTL-  
282 based assay can elucidate PAM requirements for CRISPR-Cas systems, where the assay  
283 opens the door to the rapid and scalable characterization of PAM requirements for novel Cas  
284 nucleases.

285

## 286 **DISCUSSION**

287 We have demonstrated that *E. coli* cell-free TXTL can be used for the rapid characterization of  
288 CRISPR nucleases, guide RNAs, and anti-CRISPR proteins. Unlike *in vitro* biochemical assays  
289 or cell-based assays, TXTL does not require any protein purification or cell culturing and  
290 transformation. TXTL also allows exquisite control over the reaction conditions and the amount  
291 of the DNA templates, and it can provide a dynamic and quantitative readout of nuclease activity  
292 within a few hours. We exploit these capabilities by (1) demonstrating DNA binding and  
293 cleavage by multiple types of Cas nucleases, (2) extracting the dynamics of component  
294 expression, complex formation, and DNA targeting, (3) show that the strength of gene  
295 repression strongly correlates between TXTL and *E. coli*, (4) characterize the inhibitory strength  
296 of anti-CRISPR proteins, and (5) devise a rapid PAM determination assay. With recent  
297 advances in DNA synthesis as well as liquid handling systems, these approaches could be  
298 readily scaled to hundreds of reaction conditions or constructs.

299 CRISPR-Cas systems are remarkably diverse, with significant sequence, structural, and  
300 functional diversity (Koonin et al., 2017). This diversity exists even within a single subtype; for  
301 instance, Cas9 proteins from the well-characterized Type II-A subtype can exhibit less than 10%  
302 sequence homology at the amino-acid level and show a range of recognized PAM lengths and  
303 sequences (Fonfara et al., 2014). However, only a few representative nucleases have been  
304 characterized for the other subtypes. This is particularly striking for Type I and III CRISPR-Cas  
305 systems, the most prevalent types in prokaryotes. The issue is that these systems rely on  
306 multiple proteins to form the effector complex, requiring the purification or expression of multiple  
307 proteins in defined stoichiometries that has complicated their widespread characterization. TXTL  
308 is ideally suited to characterize these multi-subunit effector complexes from these systems  
309 because linear, chemically synthesized DNA encoding each subunit can be combined in a  
310 single TXTL reaction. The expressed complex can then be characterized in a variety of ways,  
311 such as determining its assembly kinetics (see below) and PAM requirements. Evaluating  
312 numerous systems from one subtype could help reveal how CRISPR-Cas systems evolved and  
313 the structural basis of PAM recognition through mapping sequence-function relationships.

314 While our results demonstrate the promise of TXTL for characterizing CRISPR-Cas  
315 systems, there are multiple opportunities to further expand the utility of TXTL. For example,  
316 TXTL could be used to investigate spacer acquisition across the diversity of Cas acquisition  
317 proteins found in nature. Our demonstration of the strong correlation between CRISPR-based  
318 repression *in vivo* and *in vitro* also suggests that TXTL could provide a rapid means to  
319 functionally validate guide RNAs before they are deployed for genome editing. However, more  
320 research is need to determine how binding or cleavage activity in TXTL correlates to genome  
321 editing and gene regulation in prokaryotic or eukaryotic cells or whether cellular factors such as  
322 DNA repair pathways or heterochromatin formation principally determine targeting efficiency.  
323 Next, we envision the development of further high-throughput screening assays using TXTL,  
324 such as assessing the sequence-dependence of guide RNA activity. Finally, measuring the time

325 to repression with or without pre-expression of the CRISPR machinery opens the potential of  
326 using TXTL to rapidly measure the kinetics of ribonucleoprotein complex assembly and function  
327 under *in vivo*-like conditions. Through the demonstrations reported here and through further  
328 extensions, TXTL has the potential to make a widespread impact on the characterization of  
329 CRISPR-Cas systems and their transition into a new generation of CRISPR technologies.

330

### 331 **ACKNOWLEDGEMENTS**

332 We thank Ryan Leenay for help generating the FnCpf1 PAM wheel, and Jennie Fagan for  
333 cloning the plasmid expressing SpyCas9. Preliminary experiments were performed during the  
334 2016 CSHL Synthetic Biology summer course. This material is based upon work supported by  
335 the Defense Advanced Research Projects Agency (contract HR0011-16-C-01-34, V.N. and  
336 C.L.B.), the Office of Naval Research (award N00014-13-1-0074, V.N.), the National Institutes  
337 of Health (grant 1R35GM119561-01, C.L.B.), and the National Science Foundation (grant  
338 CBET-1403135 to C.L.B.).

339

### 340 **AUTHOR CONTRIBUTIONS**

341 C.L.B. designed the experiments and wrote the paper. V.N. designed the experiments and  
342 wrote the paper. C.S.M. designed and performed the experiments and wrote the paper. R.M.  
343 designed and performed the experiments and wrote the paper. M.L.L. designed and performed  
344 the experiments. T.J. performed the experiments. S.P.C. performed the experiments.

345 **REFERENCES**

- 346 Abudayyeh, O.O., Gootenberg, J.S., Konermann, S., Joung, J., Slaymaker, I.M., Cox, D.B.,  
347 Shmakov, S., Makarova, K.S., Semenova, E., Minakhin, L., *et al.* (2016). C2c2 is a single-  
348 component programmable RNA-guided RNA-targeting CRISPR effector. *Science* 353,  
349 aaf5573.
- 350 Barrangou, R., and Doudna, J.A. (2016). Applications of CRISPR technologies in research and  
351 beyond. *Nat Biotechnol* 34, 933-941.
- 352 Bikard, D., Jiang, W.Y., Samai, P., Hochschild, A., Zhang, F., and Marraffini, L.A. (2013).  
353 Programmable repression and activation of bacterial gene expression using an engineered  
354 CRISPR-Cas system. *Nucleic Acids Res* 41, 7429-7437.
- 355 Bondy-Denomy, J., Garcia, B., Strum, S., Du, M., Rollins, M.F., Hidalgo-Reyes, Y., Wiedenheft,  
356 B., Maxwell, K.L., and Davidson, A.R. (2015). Multiple mechanisms for CRISPR-Cas inhibition  
357 by anti-CRISPR proteins. *Nature* 526, 136-139.
- 358 Boyle, E.A., Andreasson, J.O.L., Chircus, L.M., Sternberg, S.H., Wu, M.J., Guegler, C.K.,  
359 Doudna, J.A., and Greenleaf, W.J. (2017). High-throughput biochemical profiling reveals  
360 sequence determinants of dCas9 off-target binding and unbinding. *Proc Natl Acad Sci U S A*  
361 114, 5461-5466.
- 362 Carlson, E.D., Gan, R., Hodgman, C.E., and Jewett, M.C. (2011). Cell-free protein synthesis:  
363 Applications come of age. *Biotechnol Adv.*
- 364 Caschera, F., and Noireaux, V. (2014). Synthesis of 2.3 mg/ml of protein with an all *Escherichia*  
365 *coli* cell-free transcription-translation system. *Biochimie* 99, 162-168.
- 366 Chappell, J., Jensen, K., and Freemont, P.S. (2013). Validation of an entirely in vitro approach  
367 for rapid prototyping of DNA regulatory elements for synthetic biology. *Nucleic Acids Res* 41,  
368 3471-3481.
- 369 Chen, B., Guan, J., and Huang, B. (2016). Imaging Specific Genomic DNA in Living Cells.  
370 *Annual review of biophysics* 45, 1-23.



- 371 Dominguez, A.A., Lim, W.A., and Qi, L.S. (2016). Beyond editing: repurposing CRISPR-Cas9  
372 for precision genome regulation and interrogation. *Nature reviews. Molecular cell biology* 17,  
373 5-15.
- 374 Dudley, Q.M., Karim, A.S., and Jewett, M.C. (2014). Cell-free metabolic engineering:  
375 Biomanufacturing beyond the cell. *Biotechnol J*.
- 376 Fonfara, I., Le Rhun, A., Chylinski, K., Makarova, K.S., Lecrivain, A.L., Bzdrenga, J., Koonin,  
377 E.V., and Charpentier, E. (2014). Phylogeny of Cas9 determines functional exchangeability of  
378 dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems. *Nucleic Acids Res* 42,  
379 2577-2590.
- 380 Fonfara, I., Richter, H., Bratovic, M., Le Rhun, A., and Charpentier, E. (2016). The CRISPR-  
381 associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA. *Nature* 532,  
382 517-521.
- 383 Garamella, J., Marshall, R., Rustad, M., and Noireaux, V. (2016). The All E. coli TX-TL Toolbox  
384 2.0: A Platform for Cell-Free Synthetic Biology. *ACS Synth Biol*.
- 385 Gilbert, L.A., Horlbeck, M.A., Adamson, B., Villalta, J.E., Chen, Y., Whitehead, E.H., Guimaraes,  
386 C., Panning, B., Ploegh, H.L., Bassik, M.C., *et al.* (2014). Genome-Scale CRISPR-Mediated  
387 Control of Gene Repression and Activation. *Cell* 159, 647-661.
- 388 Gootenberg, J.S., Abudayyeh, O.O., Lee, J.W., Essletzbichler, P., Dy, A.J., Joung, J., Verdine,  
389 V., Donghia, N., Daringer, N.M., Freije, C.A., *et al.* (2017). Nucleic acid detection with  
390 CRISPR-Cas13a/C2c2. *Science* 356, 438-442.
- 391 Hockenberry, A.J., and Jewett, M.C. (2012). Synthetic in vitro circuits. *Curr Opin Chem Biol* 16,  
392 253-259.
- 393 Jewett, M.C., Calhoun, K.A., Voloshin, A., Wu, J.J., and Swartz, J.R. (2008). An integrated  
394 cell-free metabolic platform for protein production and synthetic biology. *Mol Syst Biol* 4, 220.
- 395 Jiang, W., Bikard, D., Cox, D., Zhang, F., and Marraffini, L.A. (2013). RNA-guided editing of  
396 bacterial genomes using CRISPR-Cas systems. *Nat Biotechnol* 31, 233-239.

397 Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., and Charpentier, E. (2012). A  
398 programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*  
399 337, 816-821.

400 Kanter, G., Yang, J., Voloshin, A., Levy, S., Swartz, J.R., and Levy, R. (2007). Cell-free  
401 production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines.  
402 *Blood* 109, 3393-3399.

403 Karvelis, T., Gasiunas, G., and Siksnys, V. (2017). Methods for decoding Cas9 protospacer  
404 adjacent motif (PAM) sequences: A brief overview. *Methods* 121-122, 3-8.

405 Karvelis, T., Gasiunas, G., Young, J., Bigelyte, G., Silanskas, A., Cigan, M., and Siksnys, V.  
406 (2015). Rapid characterization of CRISPR-Cas9 protospacer adjacent motif sequence  
407 elements. *Genome biology* 16, 253.

408 Karzbrun, E., Tayar, A.M., Noireaux, V., and Bar-Ziv, R.H. (2014). Programmable on-chip DNA  
409 compartments as artificial cells. *Science* 345, 829-832.

410 Kim, E., Koo, T., Park, S.W., Kim, D., Kim, K., Cho, H.Y., Song, D.W., Lee, K.J., Jung, M.H.,  
411 Kim, S., *et al.* (2017). In vivo genome editing with a small Cas9 orthologue derived from  
412 *Campylobacter jejuni*. *Nature communications* 8, 14500.

413 Kleinstiver, B.P., Tsai, S.Q., Prew, M.S., Nguyen, N.T., Welch, M.M., Lopez, J.M., McCaw, Z.R.,  
414 Aryee, M.J., and Joung, J.K. (2016). Genome-wide specificities of CRISPR-Cas Cpf1  
415 nucleases in human cells. *Nat Biotechnol* 34, 869-874.

416 Komor, A.C., Badran, A.H., and Liu, D.R. (2017). CRISPR-Based Technologies for the  
417 Manipulation of Eukaryotic Genomes. *Cell* 168, 20-36.

418 Koonin, E.V., Makarova, K.S., and Zhang, F. (2017). Diversity, classification and evolution of  
419 CRISPR-Cas systems. *Curr Opin Microbiol* 37, 67-78.

420 Leenay, R.T., and Beisel, C.L. (2017). Deciphering, Communicating, and Engineering the  
421 CRISPR PAM. *J Mol Biol* 429, 177-191.

422 Leenay, R.T., Maksimchuk, K.R., Slotkowski, R.A., Agrawal, R.N., Gomaa, A.A., Briner, A.E.,  
423 Barrangou, R., and Beisel, C.L. (2016). Identifying and Visualizing Functional PAM Diversity  
424 across CRISPR-Cas Systems. *Mol Cell* 62, 137-147.

425 Luo, M.L., Mullis, A.S., Leenay, R.T., and Beisel, C.L. (2015). Repurposing endogenous type I  
426 CRISPR-Cas systems for programmable gene repression. *Nucleic Acids Res* 43, 674-681.

427 Makarova, K.S., Wolf, Y.I., Alkhnbashi, O.S., Costa, F., Shah, S.A., Saunders, S.J., Barrangou,  
428 R., Brouns, S.J., Charpentier, E., Haft, D.H., *et al.* (2015). An updated evolutionary  
429 classification of CRISPR-Cas systems. *Nat Rev Microbiol* 13, 722-736.

430 Marshall, R., Maxwell, C.S., Collins, S.P., Beisel, C.L., and Noireaux, V. (2017). Short DNA  
431 containing chi sites enhances DNA stability and gene expression in *E. coli* cell-free  
432 transcription-translation systems. *Biotechnol Bioeng* 114, 2137-2141.

433 Mohanraju, P., Makarova, K.S., Zetsche, B., Zhang, F., Koonin, E.V., and van der Oost, J.  
434 (2016). Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems.  
435 *Science* 353, aad5147.

436 Mulepati, S., and Bailey, S. (2013). In vitro reconstitution of an *Escherichia coli* RNA-guided  
437 immune system reveals unidirectional, ATP-dependent degradation of DNA target. *J Biol*  
438 *Chem* 288, 22184-22192.

439 Nelles, D.A., Fang, M.Y., O'Connell, M.R., Xu, J.L., Markmiller, S.J., Doudna, J.A., and Yeo,  
440 G.W. (2016). Programmable RNA Tracking in Live Cells with CRISPR/Cas9. *Cell* 165, 488-  
441 496.

442 Pardee, K., Slomovic, S., Nguyen, P.Q., Lee, J.W., Donghia, N., Burrill, D., Ferrante, T.,  
443 McSorley, F.R., Furuta, Y., Vernet, A., *et al.* (2016). Portable, On-Demand Biomolecular  
444 Manufacturing. *Cell* 167, 248-259 e212.

445 Pattanayak, V., Lin, S., Guilinger, J.P., Ma, E., Doudna, J.A., and Liu, D.R. (2013). High-  
446 throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease  
447 specificity. *Nat Biotechnol* 31, 839-843.

448 Pawluk, A., Amrani, N., Zhang, Y., Garcia, B., Hidalgo-Reyes, Y., Lee, J., Edraki, A., Shah, M.,  
449 Sontheimer, E.J., Maxwell, K.L., *et al.* (2016a). Naturally Occurring Off-Switches for CRISPR-  
450 Cas9. *Cell* *167*, 1829-1838 e1829.

451 Pawluk, A., Staals, R.H., Taylor, C., Watson, B.N., Saha, S., Fineran, P.C., Maxwell, K.L., and  
452 Davidson, A.R. (2016b). Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in  
453 diverse bacterial species. *Nature microbiology* *1*, 16085.

454 Qi, L.S., Larson, M.H., Gilbert, L.A., Doudna, J.A., Weissman, J.S., Arkin, A.P., and Lim, W.A.  
455 (2013). Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of  
456 Gene Expression. *Cell* *152*, 1173-1183.

457 Rath, D., Amlinger, L., Hoekzema, M., Devulapally, P.R., and Lundgren, M. (2015). Efficient  
458 programmable gene silencing by Cascade. *Nucleic Acids Res* *43*, 237-246.

459 Rauch, B.J., Silvis, M.R., Hultquist, J.F., Waters, C.S., McGregor, M.J., Krogan, N.J., and  
460 Bondy-Denomy, J. (2017). Inhibition of CRISPR-Cas9 with Bacteriophage Proteins. *Cell* *168*,  
461 150-158 e110.

462 Schmidt, R., Bukau, B., and Mogk, A. (2009). Principles of general and regulatory proteolysis by  
463 AAA+ proteases in *Escherichia coli*. *Res Microbiol* *160*, 629-636.

464 Shin, J., and Noireaux, V. (2012). An *E. coli* cell-free expression toolbox: application to synthetic  
465 gene circuits and artificial cells. *ACS Synth Biol* *1*, 29-41.

466 Shmakov, S., Abudayyeh, O.O., Makarova, K.S., Wolf, Y.I., Gootenberg, J.S., Semenova, E.,  
467 Minakhin, L., Joung, J., Konermann, S., Severinov, K., *et al.* (2015). Discovery and Functional  
468 Characterization of Diverse Class 2 CRISPR-Cas Systems. *Mol Cell* *60*, 385-397.

469 Sun, Z.Z., Yeung, E., Hayes, C.A., Noireaux, V., and Murray, R.M. (2014). Linear DNA for Rapid  
470 Prototyping of Synthetic Biological Circuits in an *Escherichia coli* Based TX-TL Cell-Free  
471 System. *Acs Synthetic Biology* *3*, 387-397.

472 Swartz, J. (2006). Developing cell-free biology for industrial applications. *J Ind Microbiol*  
473 *Biotechnol* *33*, 476-485.

474 Takahashi, M.K., Chappell, J., Hayes, C.A., Sun, Z.Z., Kim, J., Singhal, V., Spring, K.J., Al-  
475 Khabouri, S., Fall, C.P., Noireaux, V., *et al.* (2015a). Rapidly Characterizing the Fast  
476 Dynamics of RNA Genetic Circuitry with Cell-Free Transcription-Translation (TX-TL) Systems.  
477 *ACS Synth Biol* 4, 503-515.

478 Takahashi, M.K., Hayes, C.A., Chappell, J., Sun, Z.Z., Murray, R.M., Noireaux, V., and Lucks,  
479 J.B. (2015b). Characterizing and prototyping genetic networks with cell-free transcription-  
480 translation reactions. *Methods*.

481 Tayar A., K.E., Noireaux V., Bar-Ziv R. (2015). Propagating gene expression fronts in a one-  
482 dimensional coupled system of artificial cells. *Nature Physics*.

483 Tsai, S.Q., Nguyen, N.T., Malagon-Lopez, J., Topkar, V.V., Aryee, M.J., and Joung, J.K. (2017).  
484 CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-  
485 targets. *Nature methods* 14, 607-614.

486 Westra, E.R., van Erp, P.B., Kunne, T., Wong, S.P., Staals, R.H., Seegers, C.L., Bollen, S.,  
487 Jore, M.M., Semenova, E., Severinov, K., *et al.* (2012). CRISPR immunity relies on the  
488 consecutive binding and degradation of negatively supercoiled invader DNA by Cascade and  
489 Cas3. *Mol Cell* 46, 595-605.

490 Zetsche, B., Gootenberg, J.S., Abudayyeh, O.O., Slaymaker, I.M., Makarova, K.S.,  
491 Essletzbichler, P., Volz, S.E., Joung, J., van der Oost, J., Regev, A., *et al.* (2015). Cpf1 is a  
492 single RNA-guided endonuclease of a class 2 CRISPR-Cas system. *Cell* 163, 759-771.

493 Zetsche, B., Heidenreich, M., Mohanraju, P., Fedorova, I., Kneppers, J., DeGennaro, E.M.,  
494 Winblad, N., Choudhury, S.R., Abudayyeh, O.O., Gootenberg, J.S., *et al.* (2017). Multiplex  
495 gene editing by CRISPR-Cpf1 using a single crRNA array. *Nat Biotechnol* 35, 31-34.

496

## 497 **MATERIALS AND METHODS**

498 **Preparation of TXTL lysates and reactions.** The *E. coli* cell-free TXTL lysate was prepared  
499 from BL21 Rosetta 2 from Novagen as described previously (Caschera and Noireaux, 2014).

500 The dSpyCas9-loaded TXTL lysate followed the same procedure, only the *E. coli* cells harbored  
501 a plasmid constitutively expressing dSpyCas9 from a J23108 promoter. TXTL reactions were  
502 composed of 33% volume crude extract and the remaining 67% volume with the following  
503 components: energy mix, amino acid mix, cofactors, ions, and DNA. A typical TXTL reaction  
504 contains 50 mM HEPES pH 8, 1.5 mM ATP and GTP, 0.9 mM CTP and UTP, 0.2 mg/mL tRNA,  
505 0.26 mM coenzyme A, 0.33 mM NAD, 0.75 mM cAMP, 0.068 mM folinic acid, 1 mM spermidine,  
506 30 mM 3-PGA, 1.5% PEG8000, 30 mM maltodextrin, 3 mM of each of the 20 amino acids, 90  
507 mM K-glutamate, and 4 mM Mg-glutamate. TXTL reactions were conducted in volumes of 5  $\mu$ l  
508 at 29-30°C. When expressing from linear DNA template, 2  $\mu$ M of annealed oligos containing six  
509 copies of the  $\chi$ -site sequence (Chi6; for details see (Marshall et al., 2017)) was added to the  
510 reaction.

511  
512 **Assembly of expression constructs.** Plasmids were constructed using standard techniques.  
513 The sequence of each gBlock and plasmid used in this experiment is available in the supporting  
514 information (Table S1). The plasmid expressing catalytically active SpyCas9 was generated by  
515 amplifying the transcriptional unit expressing SpyCas9 from pCas9 but excluding the CRISPR  
516 array from using primers CSMpr1132/1157 and cloning it into the backbone pCSM117. pCas9  
517 was a gift from Luciano Maraffini (Addgene plasmid #42876). gBlocks were ordered from IDT  
518 and amplified with CSMpr1105/1106 before being PCR purified. All constructed plasmids were  
519 verified by Sanger sequencing of the inserted sequences.

520  
521 **Fluorescence time-course measurements in TXTL.** Fluorescence kinetics measurements  
522 were performed principally using the reporter plasmid P70a-deGFP expressing a truncated  
523 version of eGFP (deGFP, 25.4 kDa, 1 mg/mL = 39.38  $\mu$ M) (Shin and Noireaux, 2012).  
524 Fluorescence was measured on a Biotek H1m plate reader using a 96-well V-bottom plate  
525 (Corning Costar 3357) and Ex 485 nm, Em 528 nm. Time-course measurements were run for at

526 least 16 hours at 29-30°C, with an interval of 3 minutes between reads. Fluorescence intensity  
527 measurements were quantified using a linear standard curve, spanning over three orders of  
528 magnitude, produced with pure recombinant eGFP (Cell Biolabs Inc., San Diego, CA). Error  
529 bars are the standard error of measurement based on at least three replicates run on the same  
530 day. GFP production rates were calculated by two-point numerical differentiation and smoothed  
531 with a five-point quadratic polynomial. The time to repression was calculated based on the  
532 earliest time in which the rates of deGFP production diverge for the targeting sgRNA and the  
533 non-targeting sgRNA.

534

535 **Amplification of DNA targets in TXTL.** TXTL reactions with the SpyCas9 or dSpyCas9  
536 plasmid, sgRNA DNA template, and the P70a-deGFP expression plasmid were incubated at  
537 29°C for three hours, then diluted 200X in water. 1 µl of this dilution was then used as the DNA  
538 template in a 50 µl PCR reaction with 55°C annealing temperature, 45 s extension time, and 25  
539 cycles. The PCR reaction was conducted using Taq polymerase and primers RM01s and  
540 RM05as to produce a 1074-bp amplicon. PCR products were visualized on a 0.8% agarose gel.

541

542 **Fluorescence measurements in *E. coli*.** *E. coli* K-12 MG1655 cells with plasmids expressing  
543 dSpyCas9 and deGFP was transformed by electroporation with plasmids encoding the sgRNAs  
544 targeting sites (g1-19 targeting) on deGFP, as well as a non-targeting control (g-nt). To measure  
545 each strain, three colonies from a freshly streaked plate was inoculated into 2 mL of LB with 34  
546 µg/ml chloramphenicol (Cm), 50 µg/ml ampicillin (Amp), and 50 µg/ml kanamycin (Kan). The  
547 strains were cultured for 16-hours at 37° C shaking at 250 rpm. The cultures were then diluted  
548 1:10,000 in LB with Cm, Amp, and Kan to a final volume of 100 µL within a black 96-well assay  
549 plate. Each culture was diluted into two wells as technical replicates. Cultures were incubated at  
550 37° C with single orbital shaking at 425 rpm on a 3 mm diameter circle within a BioTek Synergy  
551 H1 for 20 hours at which cultures were in stationary phase. Cultures were resuspended with a

552 multichannel pipette and loaded back into the BioTek Synergy H1. Single-point fluorescence at  
553 485/528 nm excitation/emission as well as OD<sub>600</sub> were measured from each well. Endpoint  
554 fluorescence values were background subtracted using the fluorescence from cells lacking  
555 deGFP and then normalized by the endpoint, background-subtracted OD<sub>600</sub> value. Fold  
556 repression was then calculated as the normalized fluorescence of the non-targeting sgRNA  
557 strain divided by the normalized fluorescence of the targeting sgRNA strain.


558

559 **TXTL-based PAM assay.** The pET vector expressing FnCpf1 was a kind gift of Benson Hill  
560 Biosystems. A PAM library with five randomized nucleotides flanking the spacer sequence was  
561 prepared as described previously (Leenay et al., 2016). The crRNA expressing the FnCpf1  
562 crRNA targeting the PAM library was expressed from the gBlock CSM-GB099. A TXTL reaction  
563 was assembled as described above except the reaction contained 0.5 mM IPTG and the  
564 following DNA components: 0.2 nM P70a-T7RNAP, 2 nM pET-FnCpf1, 2 μM of Chi6 annealed  
565 oligos, 0.5 nM of the 5N PAM library, 2 nM of linear DNA expressing the crRNA. The reaction  
566 was split into 5 μL reactions as above and incubated at 29°C. Samples were then collected at  
567 the specified time by cutting away the cap mat sealing individual reactions and immediately  
568 freezing the reaction at -20°C until subsequent use. The adapters were attached by PCR  
569 amplification of the TXTL reaction using NEB's Q5 High-Fidelity DNA Polymerase with RL133  
570 and RL134. The PCR reaction was then purified using Ampure beads before attaching unique  
571 Nextera indices to each sample by PCR amplification. After a final PCR purification using  
572 Ampure beads, each sample was normalized to 10 nM in a total volume of 20 uL and submitted  
573 for next-generation sequencing with 150 single-end reads on an Illumina MiSeq machine. The  
574 PAM wheel was generated as described previously (Leenay et al., 2016).

575



576 **FIGURE LEGENDS**



577

578 **Figure 1.** *S. pyogenes* Cas9 functions efficiently in TXTL. **A.** Schematic of using TXTL to

579 dynamically and quantitatively measure the activity of Cas9 and the catalytically-dead Cas9

580 (dCas9) repression based on repressing expression of a deGFP reporter construct. Plasmids

581 expressing a reporter gene (deGFP) and SpyCas9 or dSpyCas9 as well as linear DNA

582 expressing an sgRNA are added to the cell-free reaction. sgRNAs direct the Cas9 or dCas9


583 ribonucleoprotein (RNP) complex to the reporter construct, leading to cleavage or binding by the

584 RNP, respectively. Cleavage or binding can be monitored based on GFP fluorescence over time

585 in a microplate reader. **B.** Time series showing deGFP concentration for cell-free reactions


586 expressing either Cas9 or dCas9 and a non-targeting sgRNA (green) or targeting sgRNAs  
587 (blue). Target locations include the sequence matching the guide (blue line) and the PAM  
588 (yellow circle). **C.** Alternative sigma factors  $\sigma_{28}$ ,  $\sigma_{38}$ , and  $\sigma_{54}$  and the T7 polymerase can be  
589 expressed in TXTL from the  $P_{70a}$  promoter and activate their cognate promoters  $P_{28a}$ ,  $P_{38a}$ ,  $P_{54a}$ ,  
590 and  $P_{T7}$ , respectively. A matrix showing dSpyCas9-based repression of promoters dependent  
591 on  $\sigma_{28}$ ,  $\sigma_{38}$ ,  $\sigma_{54}$  and the T7 polymerase is shown. An sgRNA targeting each promoter or the  
592 GFP gene body was expressed along with each sigma factor or polymerase and a reporter  
593 gene driven by the sigma factor of its cognate promoter. For each condition, repression was  
594 calculated after a reaction time of 16 hours in comparison to a non-targeting sgRNA.

595




596  
 597 **Figure 2.** Multiple factors affect dSpyCas9-based repression of reporter gene expression in  
 598 TXTL. **A.** Locations within the deGFP reporter construct targeted with the sgRNAs. Target  
 599 locations include the sequence matching the guide (blue line) and the PAM (yellow circle). **B.**  
 600 Fold-repression for reporter constructs encoding deGFP or deGFP-ssrA. The ssrA degron tag is  
 601 recognized by the ClpXP protease that results in rapid turnover of the fusion protein. Fold-  
 602 repression is the ratio of deGFP concentrations after 16 hours of reaction for the non-targeting  
 603 (green) over the targeting (blue) sgRNA. **C.** Fold-repression produced by a TXTL reaction when  
 604 deGFP is expressed from either a targeted linear or plasmid construct. **D.** Time series showing  
 605 deGFP concentration in TXTL for cell-free reactions expressing dSpyCas9 and a targeting

606 sgRNA. The reporter plasmid is added to the reaction either at the same time as dCas9 and the  
607 sgRNA (top row) or after a 3 hour pre-expression of dSpyCas9 and the sgRNA (bottom row).



608

609 **Figure 3.** dSpyCas9-based repression *in vivo* and *in vitro* are well-correlated. A schematic of  
 610 where each guide binds in the GFP promoter and gene body is shown (top). The location of the  
 611 target and PAM are indicated by a blue line and a yellow or orange dot, respectively. The fold-  
 612 repression of GFP production by CRISPRi for a guide RNA *in vivo* and *in vitro* is shown  
 613 (bottom). Points are colored by whether the guide is adjacent to an NGG (yellow) or NAG  
 614 (orange) PAM, and whether the sgRNA targets the non-template (black ring) or non-template  
 615 (gray ring) strand.



616

617 **Figure 4.** Single effector and multi-protein effector Cas proteins function efficiently in TXTL.

618 Time series of reporter gene expression in TXTL for cell-free reactions expressing **A.** a

619 catalytically inactive version of the Type V-A Cpf1 nuclease from *Francisella novicida* or **B.** the

620 Type I-E Cascade complex from *E. coli*. The protein or set of proteins were expressed along


621 with a non-targeting guide RNA (green) or one of three guide RNAs (blue) designed to target

622 the promoter of the deGFP reporter construct. The reporter plasmid is added to the reaction

623 either at the same time as the constructs expressing the Cas protein(s) and the guide RNA (top

624 row) or after three hours of pre-expression (bottom row). The guide RNAs were expressed as a

625 mature CRISPR RNA (FnCpf1) or as a repeat-spacer-repeat (EcCascade).



626

627 **Figure 5.** Using TXTL to characterize anti-CRISPR proteins and to determine PAMs. **A.** Time  
 628 series of deGFP-ssrA expression in TXTL for cell-free reactions also expressing dSpyCas9, an  
 629 sgRNA, and one of two anti-CRISPR proteins, AcrIIA2 and AcrIIA4, shown to inhibit SpyCas9  
 630 activity. Each reaction was performed with a targeting sgRNA (blue) or a non-targeting sgRNA  
 631 (green). **B.** Schematic of a TXTL-based cleavage assay to determine the PAM sequences

632 recognized by Cas nucleases. Plasmids expressing the Cas nuclease and a guide RNA  
633 targeting a sequence flanked by randomized base pairs are combined and incubated in TXTL.  
634 Plasmids containing valid PAMs are cleaved by the Cas nuclease, while plasmids lacking a  
635 PAM are uncut. Sequencing libraries are then created by PCR amplifying across the target site,  
636 resulting in depletion of PAM sequences in the subsequent sequencing library. **C.** Plots showing  
637 the fold-change in the representation of a nucleotide at each variable position in the PAM library  
638 in comparison to the original PAM library. Note that the y-axis is inverted to highlight nucleotides  
639 that are depleted. **D.** Time series showing the depletion of selected motifs matching the  
640 consensus sequence in the sequencing libraries are shown. Error bars show the standard  
641 deviation of the fold-change. **E.** A PAM wheel showing the determined PAM sequences  
642 recognized by FnCpf1. PAM sequences are read proceeding from the outside to the inside of  
643 the circle, and the arc length directly correlates with the extent of PAM depletion. The -5 position  
644 was not shown for clarity.